ASCO 2012 Breast Cancer Symposium home

September 15, 2012

Article

Cancer Network presents exclusive coverage from the annual American Society of Clinical Oncology (ASCO) Breast Cancer Symposium. Check out the stories below for write-ups of the most important information to come out of this year's event.

Cancer Network presents exclusive coverage from the annual American Society of Clinical Oncology (ASCO) Breast Cancer Symposium. Check out the stories below for write-ups of the most important information to come out of this year's event.

Related Content

The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.

Neoadjuvant/Adjuvant Pembrolizumab Regimens Lower RCB in ER+ Breast Cancer

April 19th 2024

Article

The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

Surgeons Talk Key Treatment and Institutional Advances Across Oncology Care

April 15th 2024

Podcast

Experts discuss findings related to gastrointestinal cancer outcomes as well as treatment inequalities presented at the 2024 SSO Annual Meeting.

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

FDA Mandates New CAR T-Cell Therapy Boxed Warnings in Hematologic Cancers

April 19th 2024

Article

The agency recommends that all patients receiving CAR T-cell products should be monitored life-long for secondary malignancy risks.

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

Finding Ways to Break the Mold in GU Oncology

April 8th 2024

Podcast

Leaders in genitourinary oncology spoke about key research advances as well as personal experiences in navigating the field.

FDA Approves Alectinib for Early-Stage ALK+ NSCLC

April 18th 2024

Article

The FDA has approved alectinib for the adjuvant treatment of patients with ALK-positive non-small cell lung cancer with tumors that are least 4 cm or node positive, as detected by an FDA-approved test.